PTP Profile Thera.

    For Final Release                                                   2 July 2004

                           Profile Therapeutics plc                            

                         ("Profile" or the "Company")                          

                                 Board Changes                                 

Profile Therapeutics plc announces that, following yesterday's announcement on
1 July 2004 that the recommended cash offer by Respironics UK Holding Company
Limited for Profile had been declared unconditional in all respects, there have
been a number of Board changes.

John L. Miclot (age 45), President and Chief Executive Officer of Respironics,
Inc., Daniel J. Bevevino (age 44), Vice President and Chief Financial Officer
of Respironics, Inc., and Steven P. Fulton (age 45), Vice President and General
Counsel of Respironics, Inc., were appointed to the Board on 1 July 2004 as
executive directors. Mark Kirby, John Lisle, Jonathan Denyer, John Ward, John
Burke, Simon Constantine and John Padfield resigned as directors of the Company
on 1 July 2004.

John L. Miclot is a director of Medwave, Inc. and Daniel J. Bevevino is a
director of CryoLife, Inc.

The Company advises that no details have failed to be disclosed under Paragraph
16.4 of the UKLA Listing Rules.

For further information, please contact:

Buchanan Communications                                           020 7466 5000
                                                                               
Tim Anderson / James Strong                                                    



END

Profile Thera. (LSE:PTP)
Historical Stock Chart
From Oct 2024 to Nov 2024

Profile Thera. (LSE:PTP)
Historical Stock Chart
From Nov 2023 to Nov 2024